US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Relmada Therapeutics, Inc.

0.3224

+0.038313.48%

Pre-market: 0.3220-0.0004-0.12%09:27 EDT

Volume:2.30M

Turnover:713.95K

Market Cap:10.70M

PE:-0.12

High:0.3252

Open:0.2700

Low:0.2700

Close:0.2841

Loading ...

Overview Company News Filings

Relmada Therapeutics Reports 'Positive' Phase 2 Data for Bladder Cancer Treatment

MT Newswires Live

Relmada Therapeutics presents initial Phase 2 NDV-01 data at AUA2025

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

Psychedelic: Clearmind completes clinical site initiations for AUD trial

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

Relmada Therapeutics To Present NDV-01 Data at AUA2025

Q4 2024 Relmada Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents

Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights: Strategic Acquisitions and ...

Relmada Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

BRIEF-Relmada Therapeutics Q4 EPS USD -0.62

Relmada Therapeutics Q4 EPS USD -0.62

THOMSON REUTERS

Relmada Therapeutics: Expect Topline Phase 2 Data for Ndv-01 for High-Grade Non-Muscle Invasive Bladder Cancer (Hg-Nmibc)

THOMSON REUTERS

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Calendar of U.S. Earnings Expected in the Week Ahead

BRIEF-Relmada Therapeutics Inc -On March 24, Enters Exclusive License Agreement With Trigone Pharma - SEC Filing

Relmada Therapeutics Inc -on March 24, Enters Exclusive License Agreement With Trigone Pharma - SEC Filing

THOMSON REUTERS

BRIEF-Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

Relmada- to Pay up to $200 Mln in Development, Regulatory,Sales Milestones Pending Successful Commercialization

THOMSON REUTERS

Calendar of U.S. Earnings Expected in the Week Ahead

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RLMD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RLMD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RLMD\",,,,,undefined,":{"symbol":"RLMD","market":"US","secType":"STK","nameCN":"Relmada Therapeutics, Inc.","latestPrice":0.3224,"timestamp":1746043200000,"preClose":0.2841,"halted":0,"volume":2303866,"hourTrading":{"tag":"盘前","latestPrice":0.322,"preClose":0.3224,"latestTime":"09:27 EDT","volume":28914,"amount":9479.37769962,"timestamp":1746106038155},"delay":0,"floatShares":30568066,"shares":33191622,"eps":-2.651505,"marketStatus":"Pre-Mkt","change":0.0383,"latestTime":"05-01 09:27:33 EDT","open":0.27,"high":0.3252,"low":0.27,"amount":713954.1119720399,"amplitude":0.194298,"askPrice":0.37,"askSize":12000,"bidPrice":0.32,"bidSize":402,"shortable":3,"etf":0,"ttmEps":-2.651505,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1746106200000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":0.3224,"preHourTrading":{"tag":"盘前","latestPrice":0.322,"preClose":0.3224,"latestTime":"09:27 EDT","volume":28914,"amount":9479.37769962,"timestamp":1746106038155},"postHourTrading":{"tag":"盘后","latestPrice":0.328524,"preClose":0.3224,"latestTime":"19:55 EDT","volume":22720,"amount":7265.7468,"timestamp":1746057329888},"volumeRatio":0.18640070485692145,"impliedVol":1.0702,"impliedVolPercentile":0.0683},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RLMD\",,,,,undefined,":{"symbol":"RLMD","floatShares":30568066,"roa":"-73.14%","roe":"-132.33%","lyrEps":-2.651505,"volumeRatio":0.18640070485692145,"shares":33191622,"dividePrice":0,"high":0.3252,"amplitude":0.194298,"preClose":0.2841,"low":0.27,"week52Low":0.2404,"pbRate":"0.30","week52High":4.47,"institutionHeld":0,"latestPrice":0.3224,"committee":-0.935172,"eps":-2.651505,"divideRate":0,"volume":2303866,"delay":0,"ttmEps":-2.651505,"open":0.27,"prevYearClose":0.52,"fiveDayClose":0.69,"twentyDayClose":0.2736,"sixtyDayClose":0.3399},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RLMD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531944254","title":"Relmada Therapeutics Reports 'Positive' Phase 2 Data for Bladder Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2531944254","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531944254?lang=en_us&edition=fundamental","pubTime":"2025-04-29 03:03","pubTimestamp":1745867006,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics  said Friday initial results from a phase 2 trial of NDV-01 for bladder cancer were positive.The study, which was presented at the annual meeting of the American Urology Association, showed that 90% of patients achieved high-grade disease-free status after treatment, supporting NDV-01's potential as a new therapy for non-muscle invasive bladder cancer, the company said.At the three-month mark, 85% of patients responded to treatment, and all patients with carcinoma in situ showed a complete response, it added.At six months, all seven patients who were evaluated remained disease-free, including one who needed a second treatment at three months, according to the company.The drug was generally safe and well-tolerated, with only mild side effects like urinary urgency and slight pain, which resolved within a day, Relmada said.Shares of the company were down over 41% in recent trading.Price: 0.38, Change: -0.27, Percent Change: -41.30","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4007","BK4139","RLMD"],"gpt_icon":0},{"id":"2531568922","title":"Relmada Therapeutics presents initial Phase 2 NDV-01 data at AUA2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531568922","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531568922?lang=en_us&edition=fundamental","pubTime":"2025-04-29 01:46","pubTimestamp":1745862373,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics (RLMD) announced that “positive” initial data from the Phase 2 study of NDV-01 showed that 90% of patients achieved high-grade...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/relmada-therapeutics-presents-initial-phase-2-ndv-01-data-at-aua2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/relmada-therapeutics-presents-initial-phase-2-ndv-01-data-at-aua2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RLMD","BK4007","LENZ"],"gpt_icon":0},{"id":"2531558002","title":"Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531558002","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531558002?lang=en_us&edition=fundamental","pubTime":"2025-04-29 01:38","pubTimestamp":1745861880,"startTime":"0","endTime":"0","summary":"90% of patients achieved high grade disease-free status at any time point with NDV-01, demonstrating strong proof-of-concept for sustained-release “GEM/DOCE” formulation*. NDV-01 showed promising clinical activity in BCG-nave and BCG-unresponsive patients, with favorable overall tolerability. Data to be reviewed at Investor Event on April 28, 2025 at 4:30 PM ET. CORAL GABLES, Fla., April 28, 2025  -- Relmada Therapeutics, Inc. , a clinical-stage biotechnology company, today announced that positive initial data from the Phase 2 study of NDV-01 showed that 90% of patients achieved high-grade disease-free status at any time point following treatment, demonstrating strong clinical activity and supporting further development of NDV-01 for the treatment of non-muscle invasive bladder cancer . The data were presented today at the American Urology Association 2025  Annual Meeting with a data cutoff date of April 20, 2025. To register for the virtual Investor Event, click here.Overall: The trea","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/relmada-therapeutics-presents-positive-initial-173800225.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RLMD","BK4161","BK4139","LENZ","BK4007","ORR","CR"],"gpt_icon":0},{"id":"2530215933","title":"Psychedelic: Clearmind completes clinical site initiations for AUD trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2530215933","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530215933?lang=en_us&edition=fundamental","pubTime":"2025-04-25 23:30","pubTimestamp":1745595026,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on site initiations, dosing completion and clinical site partnerships.Discover outperforming stocks and invest smarter with Top Smart Score Stocks.Filter, analyze, and streamline your search for investment opportunities using  Tipranks' Stock Screener.“AUD remains one of the most urgent and underserved public health challenges globally,” said Dr. Adi Zuloff-Shani, CEO. “With millions affected and current treatments often falling short, the study initiation for our FDA-approved CMND-100 trial marks a critical step toward potentially transforming the treatment landscape for alcoholism. We are honored to collaborate with world renowned institutions such as Yale and Johns Hopkins as we advance our mission to potentially provide safe, effective, and innovative solutions for individuals those suffering from alcoholism.”“Completing dosing of all participants in Part A of our 005 tria","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-clearmind-completes-clinical-initiations-153026935.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-clearmind-completes-clinical-initiations-153026935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KTTA","BETRF","BK4539","MIRA","RLMD","BK4547","CMND","PBM","NRXP","BK4139","IXHL","QNTM","CMPS","ALID","ENTBF","AGNPF","MDXXF","OPTHF","DRUG","MNMD","MYCOF","SILO","BK4168","PHRRF","GHRS","SEEL","FLHLF","BK4007","ENVB","RVVTF","CYBN","BK4202","NUMIF","PSYGF","SPRC","ATAI","SNPX"],"gpt_icon":0},{"id":"2530501469","title":"Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2530501469","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530501469?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:00","pubTimestamp":1745496000,"startTime":"0","endTime":"0","summary":"April 28th AUA data presentation to highlight study in patients with high-gradenon-muscle invasive bladder cancer . Virtual event to be held on April 28, 2025 at 4:30 PM ET. CORAL GABLES, Fla., April 24, 2025  -- Relmada Therapeutics, Inc. , a clinical-stage biotechnology company, today announced it will host a virtual key opinion leader  event on Monday, April 28, 2025 at 4:30 PM ET. To register, please click here.The event will feature Boris Chertin, MD  and Yair Lotan, MD , who will join Relmada’s management to discuss topline efficacy and safety data from the Phase 2 study evaluating NDV-01 for the treatment of high-grade non-muscle invasive bladder cancer . The data will be presented at the American Urological Association meeting , on April 28, 2025 in Las Vegas, Nevada.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/relmada-therapeutics-host-kol-event-120000022.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LENZ","KOL","RLMD","BK4139","HST","BK4218","BK4007","BK4181","BK4588"],"gpt_icon":0},{"id":"2527159483","title":"Relmada Therapeutics To Present NDV-01 Data at AUA2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2527159483","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527159483?lang=en_us&edition=fundamental","pubTime":"2025-04-14 19:30","pubTimestamp":1744630200,"startTime":"0","endTime":"0","summary":"CORAL GABLES, Fla., April 14, 2025  -- Relmada Therapeutics, Inc. , a clinical-stage biotechnology company, today announced the presentation of an abstract at the American Urology Association , taking place from April 26-29th in Las Vegas.Prospective Open Label Study to Evaluate the Safety and Efficacy of Safety and Efficacy of intravesical sustained release Gemcitabine Docetaxel combination  in High Risk NMIBC: P2 on Apr 25. About NDV-01NDV-01 is an investigational, innovative sustained-release formulation of two complementary, well-established, chemotherapy agents, gemcitabine and docetaxel . It is designed for intravesical dosing and intended to be an in-office ready-to-use therapy that is administered rapidly and requires no anesthesia or new or dedicated equipment to employ. NDV-01 forms a spherical soft matrix within the bladder that sequesters drug and releases it as the matrix gradually dissolves.NDV-01 is protected by several patents that go out to 2038.The U.S. NMIBC market i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/relmada-therapeutics-present-ndv-01-113000967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4007","BK4139","RLMD"],"gpt_icon":0},{"id":"2522679522","title":"Q4 2024 Relmada Therapeutics Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2522679522","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522679522?lang=en_us&edition=fundamental","pubTime":"2025-03-28 19:05","pubTimestamp":1743159928,"startTime":"0","endTime":"0","summary":"Brian Ritchie; Managing Director, LifeSci Advisors, LLC; Relmada Therapeutics Inc. Sergio Traversa; Chief Executive Officer, Director; Relmada Therapeutics Inc. Maged Shenouda; Chief Financial Officer; Relmada Therapeutics Inc. Greetings and welcome to the Relmada Therapeutics Incorporated quarter four 2024 financial results call.It is now my pleasure to introduce Brian Ritchie.Thank you. Brian, you may be good.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-relmada-therapeutics-inc-110528479.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","RLMD"],"gpt_icon":0},{"id":"2522197895","title":"Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights: Strategic Acquisitions and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2522197895","media":"GuruFocus.com","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522197895?lang=en_us&edition=fundamental","pubTime":"2025-03-28 15:03","pubTimestamp":1743145411,"startTime":"0","endTime":"0","summary":"Cash Equivalents and Short-term Investments: $44.9 million as of December 31, 2024, compared to $96.3 million as of December 31, 2023.Cash Used in Operations: $8.8 million for Q4 2024, compared to $10.2 million for Q4 2023.Research and Development Expense: $11 million for Q4 2024, compared to $14.7 million for Q4 2023.General and Administrative Expense: $8.1 million for Q4 2024, compared to $12.1 million for Q4 2023.Net Loss: $18.6 million or $0.62 per share for Q4 2024, compared to $25.1 million or $0.84 per share for Q4 2023.GuruFocus has detected 2 Warning Signs with RLMD.Relmada Therapeutics Inc  has successfully acquired rights to two promising candidates, NDVA1 for non-muscle invasive bladder cancer and Sopranoon for compulsion-related disorders, enhancing their product pipeline.Q: Can you explain the process involved in the acquisition deals, particularly for NDVO1, and why these companies chose Relmada over other bidders?A: Sergio Traversa, CEO, explained that the acquisition o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/relmada-therapeutics-inc-rlmd-q4-070331586.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RLMD"],"gpt_icon":0},{"id":"2522534133","title":"Relmada Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2522534133","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522534133?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:40","pubTimestamp":1743108002,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryRelmada Therapeutics Inc RLMD.OQ reported a quarterly adjusted loss of 62 cents per share for the quarter e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nL5N3QA247:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD"],"gpt_icon":0},{"id":"2522539163","title":"BRIEF-Relmada Therapeutics Q4 EPS USD -0.62","url":"https://stock-news.laohu8.com/highlight/detail?id=2522539163","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522539163?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:05","pubTimestamp":1743105946,"startTime":"0","endTime":"0","summary":"BRIEF-Relmada Therapeutics Q4 EPS USD -0.62\n\n\nMar 27 (Reuters) - Relmada Therapeutics Q4 net income USD -18.6 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nPLX41B5DF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD"],"gpt_icon":0},{"id":"2522853996","title":"Relmada Therapeutics Q4 EPS USD -0.62","url":"https://stock-news.laohu8.com/highlight/detail?id=2522853996","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522853996?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:05","pubTimestamp":1743105901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nPLX41B5DF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RLMD","BK4007"],"gpt_icon":0},{"id":"2522539983","title":"Relmada Therapeutics: Expect Topline Phase 2 Data for Ndv-01 for High-Grade Non-Muscle Invasive Bladder Cancer (Hg-Nmibc)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522539983","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522539983?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:05","pubTimestamp":1743105901,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nPLX41B5DF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RLMD","BK4007"],"gpt_icon":0},{"id":"2522653140","title":"Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522653140","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522653140?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"Expect Topline Phase 2 data for NDV-01 for high-grade non-muscle invasive bladder cancer, to be presented at AUA 2025 in April. Advancing novel neurosteroid, sepranolone, towards Phase 2b study in Tourette syndrome with plans for evaluation in other compulsion-related disorders, including Prader-Willi Syndrome. Cash balance of $44.8 million as of December 31 2024. Management hosting conference call and webcast today at 4:30 PM ET. “An important dimension of our strategic options exploration has been the development of a portfolio of programs with near-term value drivers that can address under-served markets. While we maintain deep expertise in diseases of the central nervous system, as we evaluate strategic opportunities, the broad drug development expertise of our Team provides flexibility to be opportunistic,” commented Maged Shenouda, CFO of Relmada. “With a $44.8 million cash balance, as of December 31, 2024, and clean balance sheet, we begin the year with solid financial strength.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/relmada-therapeutics-reports-fourth-quarter-200500181.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4007","BK4139","PWS","BK4179","BK4563","CDC","RLMD","PAM","BK4505","IE00B1B80R65.USD","TS","BK4081","ALLO","BK4532"],"gpt_icon":0},{"id":"2522329609","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2522329609","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522329609?lang=en_us&edition=fundamental","pubTime":"2025-03-27 18:00","pubTimestamp":1743069600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·INmune Bio Inc.                                 4Q      (.55)  4:05 PM. ·TD SYNNEX Corp                                   1Q      2.91   8:05 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RANI","FC","BLRX","RLMD","FEMY","LNZA","PRGS","GEVO","TSAT","KYTX","ATAI","NNOX","DARE","CRDL","BW","GOVX","PVLA","REKR","UNCY","WGO","WBA","SGML","BCAB","SLRN","SPWH","TLSI","CELC","FTCI","BRZE","NUTX","BHST","EDAP","CLSD","CALC","LULU","AFMD","NCNO","IKT","INMB","MDAI","PVH","SKYH","INR","ADCT","GWH","ANGO","PENG","SDST","FBIO","WKSP"],"gpt_icon":0},{"id":"2522355038","title":"BRIEF-Relmada Therapeutics Inc -On March 24, Enters Exclusive License Agreement With Trigone Pharma - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522355038","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522355038?lang=en_us&edition=fundamental","pubTime":"2025-03-27 05:05","pubTimestamp":1743023102,"startTime":"0","endTime":"0","summary":"BRIEF-Relmada Therapeutics Inc -On March 24, Enters Exclusive License Agreement With Trigone Pharma - SEC FilingMarch 26  - Relmada Therapeutics Inc RLMD.O:RELMADA THERAPEUTICS INC -ON MARCH 24, ENTERS EXCLUSIVE LICENSE AGREEMENT WITH TRIGONE PHARMA - SEC FILINGRELMADA THERAPEUTICS INC - TO PAY $3.5 MILLION INITIAL LICENSE FEE TO TRIGONE - SEC FILINGSource text: [ID:n0001013762-25-002786]Further company coverage: RLMD.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90X2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RLMD"],"gpt_icon":0},{"id":"2522355737","title":"Relmada Therapeutics Inc -on March 24, Enters Exclusive License Agreement With Trigone Pharma - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522355737","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522355737?lang=en_us&edition=fundamental","pubTime":"2025-03-27 05:03","pubTimestamp":1743023020,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90X2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RLMD","BK4007"],"gpt_icon":0},{"id":"2522029545","title":"BRIEF-Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.","url":"https://stock-news.laohu8.com/highlight/detail?id=2522029545","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522029545?lang=en_us&edition=fundamental","pubTime":"2025-03-25 19:34","pubTimestamp":1742902448,"startTime":"0","endTime":"0","summary":"BRIEF-Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.March 25 (Reuters) - Relmada Therapeutics Inc RLMD.O:RELMADA THERAPEUTICS LICENSES PHASE 2 BLADDE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q804V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD","BK4007"],"gpt_icon":0},{"id":"2522029843","title":"Relmada- to Pay up to $200 Mln in Development, Regulatory,Sales Milestones Pending Successful Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2522029843","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522029843?lang=en_us&edition=fundamental","pubTime":"2025-03-25 19:30","pubTimestamp":1742902206,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q804V:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RLMD","BK4007"],"gpt_icon":0},{"id":"2521714099","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2521714099","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521714099?lang=en_us&edition=fundamental","pubTime":"2025-03-24 18:00","pubTimestamp":1742810400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Comp de San Bas                                  4Q       .36       AMC. ·Oklo Inc. Class A                               4Q      (.07)      AMC. ·Core & Main Inc.                                 4Q       .36       BMO. ·McCormick & Co                                 1Q       .64   6:30 AM","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCS","PDSB","PAYX","UNCY","WBA","LPTX","CNXC","WOOF","MDAI","SURG","IVA","ANTX","NUTX","SKYX","AFMD","CDLR","KOD","DLTR","RLMD","BCAB","SDST","TEN","OBIO","ALUR","IOBT","ACRV","DERM","EDAP","MKC","WGO","KBH","THRD","PAYS","IKT","RVPH","BEEM","ZURA","CLSD","XFOR","GRDN","CALC","FBIO","SLRN","GOVX","ABL","CHWY","MREO","MLKN","CTAS","CRMD"],"gpt_icon":0},{"id":"2521172612","title":"Psychedelic: Exclusive talk with biotech company Clearmind Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2521172612","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521172612?lang=en_us&edition=fundamental","pubTime":"2025-03-22 22:30","pubTimestamp":1742653811,"startTime":"0","endTime":"0","summary":"In this edition of “Psychedelic”, The Fly conducted an exclusive interview with Mark Haden, vice president of business development at Clearmind Medicine , a psychedelic pharmaceutical biotech company focused on development of therapeutics to solve underserved health problems. Here are some highlights:. Discover stocks' market position with detailed  competitor analyses.“Think of this space as being two overlapping circles, a Venn diagram,” Haden said. “There are addiction treatments, like counseling, Alcoholics Anonymous and some pharmaceutical interventions like Antabuse, naltrexone and acamprosate. I ran an addictions treatment program for 28 years and I can assure you that there is relatively low efficacy, the dropout rate is high, and the treatments tend to be very long-term. That’s the first circle.”“You can take MEAI if you are addicted to alcohol and you don’t want to stop,” Haden said. “You can add MEAI to your alcohol and we believe it will result in people drinking less. It c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-exclusive-talk-biotech-company-143011967.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-exclusive-talk-biotech-company-143011967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QNTM","PSYGF","ENTBF","SPRC","SEEL","BK4168","RLMD","SILO","BK4539","IXHL","BETRF","GHRS","CYBN","BK4547","NRXP","MNMD","CMPS","DRUG","CMND","AGNPF","ALID","FLHLF","BK4007","BK4202","MDXXF","RVVTF","SNPX","MIRA","ATAI","NUMIF","PBM","OPTHF","MYCOF","BK4139","KTTA","PHRRF"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":66,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RLMD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-27","symbol":"RLMD","fiscalQuarterEnding":"2024/12","expectedEps":-0.7,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"post","actualEps":-0.62},{"market":"US","date":"2024-11-07","symbol":"RLMD","fiscalQuarterEnding":"2024/09","expectedEps":-0.65,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-0.72},{"market":"US","date":"2024-08-07","symbol":"RLMD","fiscalQuarterEnding":"2024/06","expectedEps":-0.83,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"post","actualEps":-0.59},{"market":"US","date":"2024-05-08","symbol":"RLMD","fiscalQuarterEnding":"2024/03","expectedEps":-0.9,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"post","actualEps":-0.72},{"market":"US","date":"2024-03-19","symbol":"RLMD","fiscalQuarterEnding":"2023/12","expectedEps":-0.88,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1710820800000,"reportTimeType":"post","actualEps":-0.84}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RLMD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RLMD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":3,"updateTime":1733371200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RLMD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RLMD","date":"2025-04-30","current":-0.117902,"percent":0.965686,"low":-42.205269,"twenty":-10.063067,"median":-2.859389,"eighty":-0.677139,"high":-0.088966,"avg":-6.039257,"sd":8.079603,"marketCap":9429739},"quantilePoints":[{"date":"2020-05-01","current":-39.228299,"twenty":-5.548525,"median":-1.733041,"eighty":-0.357515,"marketCap":588628435},{"date":"2020-05-08","current":-41.169801,"twenty":-5.548525,"median":-1.733041,"eighty":-0.357515,"marketCap":617761060},{"date":"2020-05-15","current":-30.075697,"twenty":-5.548525,"median":-1.733041,"eighty":-0.357515,"marketCap":691513959},{"date":"2020-05-22","current":-30.796192,"twenty":-5.548525,"median":-1.733041,"eighty":-0.357515,"marketCap":708079898},{"date":"2020-05-29","current":-31.867019,"twenty":-5.548525,"median":-1.733041,"eighty":-0.357515,"marketCap":732700834},{"date":"2020-06-05","current":-31.503466,"twenty":-5.548525,"median":-1.733041,"eighty":-0.357515,"marketCap":724341874},{"date":"2020-06-12","current":-31.047373,"twenty":-5.548525,"median":-1.733041,"eighty":-0.357515,"marketCap":713855179},{"date":"2020-06-19","current":-31.569567,"twenty":-5.548525,"median":-1.733041,"eighty":-0.357515,"marketCap":725861685},{"date":"2020-06-26","current":-28.667758,"twenty":-5.548525,"median":-1.733041,"eighty":-0.357515,"marketCap":659141987},{"date":"2020-07-02","current":-28.277765,"twenty":-5.548525,"median":-1.733041,"eighty":-0.357515,"marketCap":650175103},{"date":"2020-07-10","current":-27.980313,"twenty":-5.548525,"median":-1.733041,"eighty":-0.357515,"marketCap":643335953},{"date":"2020-07-17","current":-27.980313,"twenty":-5.548525,"median":-1.733041,"eighty":-0.357515,"marketCap":643335953},{"date":"2020-07-24","current":-25.785779,"twenty":-5.548525,"median":-1.733041,"eighty":-0.357515,"marketCap":592878232},{"date":"2020-07-31","current":-24.040727,"twenty":-5.548525,"median":-1.733041,"eighty":-0.357515,"marketCap":552755224},{"date":"2020-08-07","current":-23.743276,"twenty":-5.700374,"median":-1.733041,"eighty":-0.357515,"marketCap":545916075},{"date":"2020-08-14","current":-19.888133,"twenty":-5.712286,"median":-1.733041,"eighty":-0.357515,"marketCap":596411270},{"date":"2020-08-21","current":-20.876662,"twenty":-5.737576,"median":-1.733041,"eighty":-0.357515,"marketCap":626055570},{"date":"2020-08-28","current":-18.637777,"twenty":-5.855718,"median":-1.733041,"eighty":-0.357515,"marketCap":558915236},{"date":"2020-09-04","current":-19.610276,"twenty":-5.948456,"median":-1.733041,"eighty":-0.357515,"marketCap":588078818},{"date":"2020-09-11","current":-19.36448,"twenty":-6.126741,"median":-1.733041,"eighty":-0.357515,"marketCap":580707803},{"date":"2020-09-18","current":-21.469779,"twenty":-6.279615,"median":-1.733041,"eighty":-0.357515,"marketCap":643842150},{"date":"2020-09-25","current":-19.66371,"twenty":-6.401962,"median":-1.733041,"eighty":-0.357515,"marketCap":589681212},{"date":"2020-10-02","current":-20.956813,"twenty":-6.49254,"median":-1.758166,"eighty":-0.357515,"marketCap":628459162},{"date":"2020-10-09","current":-20.860631,"twenty":-6.752577,"median":-1.818793,"eighty":-0.357515,"marketCap":625574851},{"date":"2020-10-16","current":-18.62709,"twenty":-13.145747,"median":-1.818793,"eighty":-0.357515,"marketCap":558594757},{"date":"2020-10-23","current":-17.814894,"twenty":-14.590145,"median":-1.853436,"eighty":-0.357515,"marketCap":534238359},{"date":"2020-10-30","current":-16.527134,"twenty":-14.890092,"median":-1.884167,"eighty":-0.357515,"marketCap":495620649},{"date":"2020-11-06","current":-17.040101,"twenty":-15.202709,"median":-1.905402,"eighty":-0.357515,"marketCap":511003637},{"date":"2020-11-13","current":-12.23902,"twenty":-15.348585,"median":-1.975556,"eighty":-0.357515,"marketCap":528986501},{"date":"2020-11-20","current":-13.854856,"twenty":-15.348585,"median":-2.000672,"eighty":-0.357515,"marketCap":598825063},{"date":"2020-11-27","current":-13.524173,"twenty":-15.348585,"median":-2.052637,"eighty":-0.357515,"marketCap":584532520},{"date":"2020-12-04","current":-13.152155,"twenty":-15.348585,"median":-2.07862,"eighty":-0.357515,"marketCap":568453410},{"date":"2020-12-11","current":-12.344237,"twenty":-15.348585,"median":-2.07862,"eighty":-0.357515,"marketCap":533534129},{"date":"2020-12-18","current":-12.663647,"twenty":-15.348585,"median":-2.160184,"eighty":-0.357515,"marketCap":547339426},{"date":"2020-12-24","current":-12.069921,"twenty":-15.348585,"median":-2.191878,"eighty":-0.357515,"marketCap":521677815},{"date":"2020-12-31","current":-12.051132,"twenty":-15.348585,"median":-2.251839,"eighty":-0.357515,"marketCap":520865738},{"date":"2021-01-08","current":-13.309981,"twenty":-15.348585,"median":-2.315052,"eighty":-0.357515,"marketCap":575274850},{"date":"2021-01-15","current":-13.854856,"twenty":-15.348585,"median":-2.359402,"eighty":-0.357515,"marketCap":598825063},{"date":"2021-01-22","current":-13.426472,"twenty":-15.348585,"median":-2.390413,"eighty":-0.361852,"marketCap":580309723},{"date":"2021-01-29","current":-12.280355,"twenty":-15.348585,"median":-2.511008,"eighty":-0.36481,"marketCap":530773069},{"date":"2021-02-05","current":-12.716255,"twenty":-15.348585,"median":-2.576427,"eighty":-0.370059,"marketCap":549613239},{"date":"2021-02-12","current":-13.704546,"twenty":-15.348585,"median":-2.617786,"eighty":-0.372159,"marketCap":592328453},{"date":"2021-02-19","current":-14.035229,"twenty":-15.348585,"median":-2.645672,"eighty":-0.372159,"marketCap":606620996},{"date":"2021-02-26","current":-12.528367,"twenty":-15.348585,"median":-2.728189,"eighty":-0.372159,"marketCap":541492476},{"date":"2021-03-05","current":-12.862808,"twenty":-15.354462,"median":-2.841532,"eighty":-0.371634,"marketCap":555947434},{"date":"2021-03-12","current":-13.779701,"twenty":-15.354462,"median":-2.841532,"eighty":-0.391734,"marketCap":595576758},{"date":"2021-03-19","current":-13.742123,"twenty":-15.354462,"median":-2.877762,"eighty":-0.424703,"marketCap":593952605},{"date":"2021-03-26","current":-9.271938,"twenty":-15.348585,"median":-2.890274,"eighty":-0.43007,"marketCap":551276015},{"date":"2021-04-01","current":-10.323333,"twenty":-15.348585,"median":-2.926862,"eighty":-0.438333,"marketCap":613788141},{"date":"2021-04-09","current":-9.923356,"twenty":-15.354462,"median":-2.987177,"eighty":-0.437014,"marketCap":590006991},{"date":"2021-04-16","current":-9.771253,"twenty":-15.354462,"median":-3.013299,"eighty":-0.437014,"marketCap":580963455},{"date":"2021-04-23","current":-10.376851,"twenty":-15.354462,"median":-3.039204,"eighty":-0.437014,"marketCap":616970126},{"date":"2021-04-30","current":-10.861329,"twenty":-15.354462,"median":-3.077954,"eighty":-0.437014,"marketCap":645775463},{"date":"2021-05-07","current":-10.236014,"twenty":-15.354462,"median":-3.096464,"eighty":-0.437014,"marketCap":608596482},{"date":"2021-05-14","current":-8.003248,"twenty":-15.354462,"median":-3.13772,"eighty":-0.437014,"marketCap":568216697},{"date":"2021-05-21","current":-8.968464,"twenty":-15.354462,"median":-3.169112,"eighty":-0.437014,"marketCap":636745344},{"date":"2021-05-28","current":-8.183043,"twenty":-15.354462,"median":-3.187536,"eighty":-0.437014,"marketCap":580981837},{"date":"2021-06-04","current":-7.12793,"twenty":-15.354462,"median":-3.192703,"eighty":-0.437014,"marketCap":506070620},{"date":"2021-06-11","current":-7.366868,"twenty":-15.354462,"median":-3.196717,"eighty":-0.437014,"marketCap":523034820},{"date":"2021-06-18","current":-7.310091,"twenty":-15.354462,"median":-3.215186,"eighty":-0.437014,"marketCap":519003723},{"date":"2021-06-25","current":-8.126266,"twenty":-15.354462,"median":-3.245915,"eighty":-0.437014,"marketCap":576950740},{"date":"2021-07-02","current":-7.71463,"twenty":-15.354462,"median":-3.278609,"eighty":-0.437014,"marketCap":547725288},{"date":"2021-07-09","current":-8.097877,"twenty":-15.354462,"median":-3.296823,"eighty":-0.437014,"marketCap":574935192},{"date":"2021-07-16","current":-7.373965,"twenty":-15.354462,"median":-3.315038,"eighty":-0.443169,"marketCap":523538707},{"date":"2021-07-23","current":-6.127228,"twenty":-15.354462,"median":-3.370574,"eighty":-0.443169,"marketCap":435022538},{"date":"2021-07-30","current":-6.150886,"twenty":-15.354462,"median":-3.371104,"eighty":-0.555367,"marketCap":436702162},{"date":"2021-08-06","current":-5.568917,"twenty":-15.354462,"median":-3.380611,"eighty":-0.578507,"marketCap":395383418},{"date":"2021-08-13","current":-4.61934,"twenty":-15.354462,"median":-3.397035,"eighty":-0.605119,"marketCap":399257730},{"date":"2021-08-20","current":-4.534433,"twenty":-15.354462,"median":-3.424324,"eighty":-0.659499,"marketCap":391919075},{"date":"2021-08-27","current":-4.890234,"twenty":-15.354462,"median":-3.448899,"eighty":-0.746275,"marketCap":422671531},{"date":"2021-09-03","current":-4.932687,"twenty":-15.354462,"median":-3.460753,"eighty":-0.821481,"marketCap":426340858},{"date":"2021-09-10","current":-5.260185,"twenty":-15.354462,"median":-3.485622,"eighty":-0.850406,"marketCap":454647095},{"date":"2021-09-17","current":-5.571511,"twenty":-15.354462,"median":-3.500762,"eighty":-0.850406,"marketCap":481555494},{"date":"2021-09-24","current":-5.882836,"twenty":-15.354462,"median":-3.51567,"eighty":-0.850406,"marketCap":508463892},{"date":"2021-10-01","current":-5.40574,"twenty":-15.354462,"median":-3.578556,"eighty":-0.970791,"marketCap":467227645},{"date":"2021-10-08","current":-5.290509,"twenty":-15.354462,"median":-3.584692,"eighty":-1.000536,"marketCap":457268043},{"date":"2021-10-15","current":-4.777025,"twenty":-15.354462,"median":-3.605816,"eighty":-1.014057,"marketCap":412886659},{"date":"2021-10-22","current":-4.815435,"twenty":-15.354462,"median":-3.628468,"eighty":-1.022224,"marketCap":416206526},{"date":"2021-10-29","current":-4.744679,"twenty":-15.354462,"median":-3.668784,"eighty":-1.054619,"marketCap":410090981},{"date":"2021-11-05","current":-5.314768,"twenty":-15.354462,"median":-3.690124,"eighty":-1.081661,"marketCap":459364801},{"date":"2021-11-12","current":-3.567592,"twenty":-15.354462,"median":-3.789733,"eighty":-1.415629,"marketCap":400053540},{"date":"2021-11-19","current":-3.187695,"twenty":-15.354462,"median":-3.789733,"eighty":-1.448079,"marketCap":357453623},{"date":"2021-11-26","current":-2.943811,"twenty":-15.354462,"median":-3.789733,"eighty":-1.458021,"marketCap":330105528},{"date":"2021-12-03","current":-2.646772,"twenty":-15.354462,"median":-3.789733,"eighty":-1.458229,"marketCap":296796951},{"date":"2021-12-10","current":-4.42415,"twenty":-15.354462,"median":-3.795557,"eighty":-1.477343,"marketCap":496104008},{"date":"2021-12-17","current":-4.705268,"twenty":-15.354462,"median":-3.795557,"eighty":-1.499231,"marketCap":527627378},{"date":"2021-12-23","current":-5.501431,"twenty":-15.354462,"median":-3.909674,"eighty":-1.532958,"marketCap":616905369},{"date":"2021-12-31","current":-5.570662,"twenty":-15.354462,"median":-4.004888,"eighty":-1.552453,"marketCap":624668672},{"date":"2022-01-07","current":-5.170108,"twenty":-15.348585,"median":-4.217285,"eighty":-1.558965,"marketCap":579752416},{"date":"2022-01-14","current":-4.91049,"twenty":-15.348585,"median":-4.421677,"eighty":-1.560442,"marketCap":550640028},{"date":"2022-01-21","current":-4.591531,"twenty":-15.348585,"median":-4.551617,"eighty":-1.56326,"marketCap":514873379},{"date":"2022-01-28","current":-4.32944,"twenty":-15.348585,"median":-4.580166,"eighty":-1.579649,"marketCap":485483730},{"date":"2022-02-04","current":-4.195923,"twenty":-15.348585,"median":-4.580166,"eighty":-1.584662,"marketCap":470511645},{"date":"2022-02-11","current":-4.569278,"twenty":-15.348585,"median":-4.605436,"eighty":-1.606919,"marketCap":512378032},{"date":"2022-02-18","current":-4.517354,"twenty":-15.348585,"median":-4.634752,"eighty":-1.627238,"marketCap":506555554},{"date":"2022-02-25","current":-5.081097,"twenty":-15.348585,"median":-4.649032,"eighty":-1.637901,"marketCap":569771026},{"date":"2022-03-04","current":-5.093459,"twenty":-15.348585,"median":-4.686724,"eighty":-1.645574,"marketCap":571157330},{"date":"2022-03-11","current":-5.498958,"twenty":-15.348585,"median":-4.748722,"eighty":-1.671902,"marketCap":616628108},{"date":"2022-03-18","current":-5.953908,"twenty":-15.348585,"median":-4.779046,"eighty":-1.671902,"marketCap":667644102},{"date":"2022-03-25","current":-6.013944,"twenty":-15.348585,"median":-4.795535,"eighty":-1.724543,"marketCap":756264367},{"date":"2022-04-01","current":-6.866406,"twenty":-15.348585,"median":-4.819018,"eighty":-1.749505,"marketCap":863463006},{"date":"2022-04-08","current":-6.209434,"twenty":-15.348585,"median":-4.84677,"eighty":-1.815329,"marketCap":780847514},{"date":"2022-04-14","current":-6.092407,"twenty":-15.348585,"median":-4.910514,"eighty":-1.818793,"marketCap":766131202},{"date":"2022-04-22","current":-5.727284,"twenty":-15.348585,"median":-4.93957,"eighty":-1.836115,"marketCap":720216309},{"date":"2022-04-29","current":-5.877078,"twenty":-15.348585,"median":-4.99703,"eighty":-1.869901,"marketCap":739053188},{"date":"2022-05-06","current":-4.443703,"twenty":-15.348585,"median":-5.010782,"eighty":-1.905402,"marketCap":636704471},{"date":"2022-05-13","current":-4.144386,"twenty":-15.348585,"median":-5.010782,"eighty":-1.940046,"marketCap":593817642},{"date":"2022-05-20","current":-4.20718,"twenty":-15.348585,"median":-5.010782,"eighty":-1.992011,"marketCap":602814879},{"date":"2022-05-27","current":-4.148572,"twenty":-15.348585,"median":-5.010782,"eighty":-2.040855,"marketCap":594417457},{"date":"2022-06-03","current":-4.058568,"twenty":-15.348585,"median":-5.010782,"eighty":-2.078009,"marketCap":581521418},{"date":"2022-06-10","current":-3.767624,"twenty":-15.348585,"median":-5.010782,"eighty":-2.07862,"marketCap":539834220},{"date":"2022-06-17","current":-3.830418,"twenty":-15.348585,"median":-5.010782,"eighty":-2.107186,"marketCap":548831457},{"date":"2022-06-24","current":-4.112989,"twenty":-15.354462,"median":-5.011529,"eighty":-2.165229,"marketCap":589319023},{"date":"2022-07-01","current":-3.830418,"twenty":-15.354462,"median":-5.011529,"eighty":-2.251839,"marketCap":548831457},{"date":"2022-07-08","current":-3.958098,"twenty":-15.354462,"median":-5.011529,"eighty":-2.306182,"marketCap":567125838},{"date":"2022-07-15","current":-4.70325,"twenty":-15.354462,"median":-5.011529,"eighty":-2.355854,"marketCap":673893051},{"date":"2022-07-22","current":-4.962798,"twenty":-15.354462,"median":-5.02511,"eighty":-2.393877,"marketCap":711081630},{"date":"2022-07-29","current":-5.358398,"twenty":-15.354462,"median":-5.051511,"eighty":-2.514569,"marketCap":767764224},{"date":"2022-08-05","current":-5.479799,"twenty":-15.354462,"median":-5.071206,"eighty":-2.577332,"marketCap":785158882},{"date":"2022-08-12","current":-5.583625,"twenty":-15.354462,"median":-5.085412,"eighty":-2.618223,"marketCap":874761073},{"date":"2022-08-19","current":-5.566356,"twenty":-15.354462,"median":-5.130803,"eighty":-2.648853,"marketCap":872055627},{"date":"2022-08-26","current":-5.658457,"twenty":-15.354462,"median":-5.14291,"eighty":-2.717642,"marketCap":886484675},{"date":"2022-09-02","current":-5.702589,"twenty":-15.354462,"median":-5.161645,"eighty":-2.789962,"marketCap":893398594},{"date":"2022-09-09","current":-6.118962,"twenty":-15.354462,"median":-5.168988,"eighty":-2.83992,"marketCap":958629919},{"date":"2022-09-16","current":-6.537255,"twenty":-15.354462,"median":-5.170108,"eighty":-2.841532,"marketCap":1024161848},{"date":"2022-09-23","current":-6.120881,"twenty":-15.354462,"median":-5.21571,"eighty":-2.8635,"marketCap":958930524},{"date":"2022-09-30","current":-7.103292,"twenty":-15.354462,"median":-5.232811,"eighty":-2.877762,"marketCap":1112840376},{"date":"2022-10-07","current":-6.569874,"twenty":-15.354462,"median":-5.260185,"eighty":-2.877762,"marketCap":1029272136},{"date":"2022-10-14","current":-1.189638,"twenty":-15.354462,"median":-5.278901,"eighty":-2.870556,"marketCap":186375211},{"date":"2022-10-21","current":-1.345059,"twenty":-15.354462,"median":-5.278901,"eighty":-2.841532,"marketCap":210724231},{"date":"2022-10-28","current":-1.256795,"twenty":-15.354462,"median":-5.278901,"eighty":-2.841532,"marketCap":196896392},{"date":"2022-11-04","current":-1.220339,"twenty":-15.354462,"median":-5.278901,"eighty":-2.789962,"marketCap":191184894},{"date":"2022-11-11","current":-1.245325,"twenty":-15.354462,"median":-5.278901,"eighty":-2.717642,"marketCap":191129939},{"date":"2022-11-18","current":-1.164918,"twenty":-15.354462,"median":-5.278901,"eighty":-2.704227,"marketCap":178789265},{"date":"2022-11-25","current":-1.029599,"twenty":-15.354462,"median":-5.278901,"eighty":-2.704227,"marketCap":158020815},{"date":"2022-12-02","current":-0.902125,"twenty":-15.354462,"median":-5.278901,"eighty":-2.704227,"marketCap":138456333},{"date":"2022-12-09","current":-0.525586,"twenty":-15.354462,"median":-5.278901,"eighty":-2.704227,"marketCap":80665864},{"date":"2022-12-16","current":-0.660905,"twenty":-15.354462,"median":-5.278901,"eighty":-2.704227,"marketCap":101434314},{"date":"2022-12-23","current":-0.590304,"twenty":-15.354462,"median":-5.278901,"eighty":-2.704227,"marketCap":90598601},{"date":"2022-12-30","current":-0.684438,"twenty":-15.354462,"median":-5.278901,"eighty":-2.704227,"marketCap":105046218},{"date":"2023-01-06","current":-0.645216,"twenty":-15.354462,"median":-5.278901,"eighty":-2.704227,"marketCap":99026377},{"date":"2023-01-13","current":-0.80799,"twenty":-15.354462,"median":-5.278901,"eighty":-2.704227,"marketCap":124008716},{"date":"2023-01-20","current":-0.933504,"twenty":-15.354462,"median":-5.278901,"eighty":-2.704227,"marketCap":143272206},{"date":"2023-01-27","current":-0.80799,"twenty":-15.354462,"median":-5.278901,"eighty":-2.704227,"marketCap":124008716},{"date":"2023-02-03","current":-0.80799,"twenty":-15.354462,"median":-5.278901,"eighty":-2.704227,"marketCap":124008716},{"date":"2023-02-10","current":-0.733467,"twenty":-15.354462,"median":-5.278901,"eighty":-2.704227,"marketCap":112571019},{"date":"2023-02-17","current":-0.719739,"twenty":-15.354462,"median":-5.278901,"eighty":-2.704227,"marketCap":110464075},{"date":"2023-02-24","current":-0.651099,"twenty":-15.354462,"median":-5.278901,"eighty":-2.704227,"marketCap":99929353},{"date":"2023-03-03","current":-0.698166,"twenty":-15.354462,"median":-5.278901,"eighty":-2.704227,"marketCap":107153162},{"date":"2023-03-10","current":-0.56677,"twenty":-15.354462,"median":-5.278901,"eighty":-2.704227,"marketCap":86986696},{"date":"2023-03-17","current":-0.484402,"twenty":-15.354462,"median":-5.278901,"eighty":-2.704227,"marketCap":74345031},{"date":"2023-03-24","current":-0.435071,"twenty":-15.354462,"median":-5.278901,"eighty":-2.704227,"marketCap":68325190},{"date":"2023-03-31","current":-0.433154,"twenty":-15.348585,"median":-5.270935,"eighty":-2.684884,"marketCap":68024198},{"date":"2023-04-06","current":-0.425488,"twenty":-15.348585,"median":-5.270935,"eighty":-2.684884,"marketCap":66820230},{"date":"2023-04-14","current":-0.490653,"twenty":-15.354462,"median":-5.278901,"eighty":-2.704227,"marketCap":77053959},{"date":"2023-04-21","current":-0.511735,"twenty":-15.354462,"median":-5.278901,"eighty":-2.644504,"marketCap":80364872},{"date":"2023-04-28","current":-0.525152,"twenty":-15.354462,"median":-5.278901,"eighty":-2.598617,"marketCap":82471816},{"date":"2023-05-05","current":-0.58265,"twenty":-15.354462,"median":-5.278901,"eighty":-2.528919,"marketCap":91501577},{"date":"2023-05-12","current":-0.664355,"twenty":-15.354462,"median":-5.278901,"eighty":-2.410667,"marketCap":95414473},{"date":"2023-05-19","current":-0.651781,"twenty":-15.354462,"median":-5.278901,"eighty":-2.359402,"marketCap":93608521},{"date":"2023-05-26","current":-0.595195,"twenty":-15.354462,"median":-5.278901,"eighty":-2.316826,"marketCap":85481736},{"date":"2023-06-02","current":-0.570046,"twenty":-15.354462,"median":-5.278901,"eighty":-2.284445,"marketCap":81869832},{"date":"2023-06-09","current":-0.588908,"twenty":-15.354462,"median":-5.278901,"eighty":-2.165229,"marketCap":84578760},{"date":"2023-06-16","current":-0.534418,"twenty":-15.354462,"median":-5.278901,"eighty":-2.143555,"marketCap":76752967},{"date":"2023-06-23","current":-0.536514,"twenty":-15.360338,"median":-5.282659,"eighty":-2.165229,"marketCap":77053959},{"date":"2023-06-30","current":-0.521844,"twenty":-15.366215,"median":-5.286416,"eighty":-2.165229,"marketCap":74947015},{"date":"2023-07-07","current":-0.52394,"twenty":-15.366215,"median":-5.286416,"eighty":-2.165229,"marketCap":75248007},{"date":"2023-07-14","current":-0.591004,"twenty":-15.366215,"median":-5.286416,"eighty":-2.165229,"marketCap":84879752},{"date":"2023-07-21","current":-0.62244,"twenty":-15.366215,"median":-5.286416,"eighty":-2.165229,"marketCap":89394632},{"date":"2023-07-28","current":-0.519748,"twenty":-15.366215,"median":-5.286416,"eighty":-2.085105,"marketCap":74646023},{"date":"2023-08-04","current":-0.546993,"twenty":-15.366215,"median":-5.286416,"eighty":-2.022579,"marketCap":78558919},{"date":"2023-08-11","current":-0.66738,"twenty":-15.366215,"median":-5.286416,"eighty":-1.995475,"marketCap":86083720},{"date":"2023-08-18","current":-0.665046,"twenty":-15.366215,"median":-5.286416,"eighty":-1.972611,"marketCap":85782728},{"date":"2023-08-25","current":-0.744385,"twenty":-15.366215,"median":-5.286416,"eighty":-1.972611,"marketCap":96016457},{"date":"2023-09-01","current":-0.788722,"twenty":-15.366215,"median":-5.286416,"eighty":-1.972611,"marketCap":101735306},{"date":"2023-09-08","current":-0.828391,"twenty":-15.366215,"median":-5.286416,"eighty":-1.972611,"marketCap":106852170},{"date":"2023-09-15","current":-0.772387,"twenty":-15.366215,"median":-5.286416,"eighty":-1.972611,"marketCap":99628361},{"date":"2023-09-22","current":-0.669713,"twenty":-15.366215,"median":-5.286416,"eighty":-1.912331,"marketCap":86384712},{"date":"2023-09-29","current":-0.686048,"twenty":-15.445182,"median":-5.286416,"eighty":-1.627406,"marketCap":88491656},{"date":"2023-10-06","current":-0.700049,"twenty":-15.518272,"median":-5.28644,"eighty":-1.900782,"marketCap":90297609},{"date":"2023-10-13","current":-0.746719,"twenty":-15.518272,"median":-5.28644,"eighty":-1.878374,"marketCap":96317449},{"date":"2023-10-20","current":-0.723384,"twenty":-15.518272,"median":-5.28644,"eighty":-1.444835,"marketCap":93307529},{"date":"2023-10-27","current":-0.732718,"twenty":-15.783249,"median":-5.288487,"eighty":-1.358874,"marketCap":94511497},{"date":"2023-11-03","current":-0.711716,"twenty":-15.783249,"median":-5.288487,"eighty":-1.26447,"marketCap":91802569},{"date":"2023-11-10","current":-0.806631,"twenty":-15.783249,"median":-5.288487,"eighty":-1.225327,"marketCap":89996616},{"date":"2023-11-17","current":-0.79584,"twenty":-15.783249,"median":-5.288487,"eighty":-1.187047,"marketCap":88792648},{"date":"2023-11-24","current":-0.782351,"twenty":-15.783249,"median":-5.288487,"eighty":-1.150072,"marketCap":87287688},{"date":"2023-11-30","current":-0.677139,"twenty":-15.828956,"median":-5.290509,"eighty":-1.129618,"marketCap":75548999},{"date":"2023-12-08","current":-0.690627,"twenty":-15.874664,"median":-5.294552,"eighty":-1.029599,"marketCap":77053959},{"date":"2023-12-15","current":-0.674441,"twenty":-15.920371,"median":-5.298596,"eighty":-0.904086,"marketCap":75248007},{"date":"2023-12-22","current":-0.79584,"twenty":-15.920371,"median":-5.298596,"eighty":-0.874579,"marketCap":88792648},{"date":"2023-12-29","current":-1.022452,"twenty":-15.966078,"median":-5.300095,"eighty":-0.866825,"marketCap":114075979},{"date":"2024-01-05","current":-0.834958,"twenty":-16.008223,"median":-5.301594,"eighty":-0.865648,"marketCap":93157033},{"date":"2024-01-12","current":-0.89296,"twenty":-16.008223,"median":-5.301594,"eighty":-0.865648,"marketCap":99628361},{"date":"2024-01-19","current":-0.919937,"twenty":-16.050367,"median":-5.303846,"eighty":-0.860157,"marketCap":102638282},{"date":"2024-01-26","current":-0.97659,"twenty":-16.008223,"median":-5.301594,"eighty":-0.860549,"marketCap":108959114},{"date":"2024-02-02","current":-1.23018,"twenty":-16.008223,"median":-5.301594,"eighty":-0.860549,"marketCap":137252365},{"date":"2024-02-09","current":-1.413628,"twenty":-16.008223,"median":-5.301594,"eighty":-0.860549,"marketCap":157719823},{"date":"2024-02-16","current":-1.421721,"twenty":-16.008223,"median":-5.301594,"eighty":-0.860549,"marketCap":158622799},{"date":"2024-02-23","current":-1.494561,"twenty":-16.008223,"median":-5.301594,"eighty":-0.860549,"marketCap":166749584},{"date":"2024-03-01","current":-1.65238,"twenty":-15.966078,"median":-5.300095,"eighty":-0.860941,"marketCap":184357618},{"date":"2024-03-08","current":-1.718475,"twenty":-15.966078,"median":-5.300095,"eighty":-0.860941,"marketCap":191731923},{"date":"2024-03-15","current":-1.356975,"twenty":-15.966078,"median":-5.300095,"eighty":-0.860941,"marketCap":151398991},{"date":"2024-03-22","current":-1.423315,"twenty":-15.966078,"median":-5.300095,"eighty":-0.860941,"marketCap":140611781},{"date":"2024-03-28","current":-1.401935,"twenty":-15.966078,"median":-5.300095,"eighty":-0.860941,"marketCap":138499587},{"date":"2024-04-05","current":-1.432478,"twenty":-16.008223,"median":-5.301594,"eighty":-0.860549,"marketCap":141517007},{"date":"2024-04-12","current":-1.423315,"twenty":-16.008223,"median":-5.301594,"eighty":-0.860549,"marketCap":140611781},{"date":"2024-04-19","current":-1.313359,"twenty":-16.008223,"median":-5.301594,"eighty":-0.860549,"marketCap":129749068},{"date":"2024-04-26","current":-1.1301,"twenty":-15.966078,"median":-5.300095,"eighty":-0.860941,"marketCap":111644547},{"date":"2024-05-03","current":-1.136209,"twenty":-15.966078,"median":-5.300095,"eighty":-0.860941,"marketCap":112248031},{"date":"2024-05-10","current":-1.21595,"twenty":-15.966078,"median":-5.300095,"eighty":-0.860941,"marketCap":114661967},{"date":"2024-05-17","current":-1.116754,"twenty":-15.966078,"median":-5.300095,"eighty":-0.860941,"marketCap":105307964},{"date":"2024-05-24","current":-0.995159,"twenty":-15.966078,"median":-5.288487,"eighty":-0.860941,"marketCap":93841768},{"date":"2024-05-31","current":-0.97276,"twenty":-15.966078,"median":-5.288487,"eighty":-0.860941,"marketCap":91729574},{"date":"2024-06-07","current":-0.97276,"twenty":-15.966078,"median":-5.282683,"eighty":-0.860941,"marketCap":91729574},{"date":"2024-06-14","current":-0.96316,"twenty":-16.008223,"median":-5.260185,"eighty":-0.860549,"marketCap":90824348},{"date":"2024-06-21","current":-0.97276,"twenty":-16.050367,"median":-5.240733,"eighty":-0.860157,"marketCap":91729574},{"date":"2024-06-28","current":-0.95676,"twenty":-16.176801,"median":-5.256648,"eighty":-0.85898,"marketCap":90220863},{"date":"2024-07-05","current":-0.96316,"twenty":-16.176801,"median":-5.256648,"eighty":-0.85898,"marketCap":90824348},{"date":"2024-07-12","current":-1.395142,"twenty":-16.176801,"median":-5.256648,"eighty":-0.85898,"marketCap":131559520},{"date":"2024-07-15","current":-1.299146,"twenty":-16.176801,"median":-5.256648,"eighty":-0.85898,"marketCap":122507260},{"date":"2024-08-02","current":-1.180751,"twenty":-16.505977,"median":-5.288487,"eighty":-0.844814,"marketCap":111342805},{"date":"2024-08-09","current":-0.799884,"twenty":-16.505977,"median":-5.288487,"eighty":-0.843291,"marketCap":69400664},{"date":"2024-08-16","current":-0.893783,"twenty":-16.505977,"median":-5.282683,"eighty":-0.835938,"marketCap":77547699},{"date":"2024-08-23","current":-0.973771,"twenty":-16.505977,"median":-5.237401,"eighty":-0.835938,"marketCap":84487765},{"date":"2024-08-30","current":-0.918127,"twenty":-16.505977,"median":-5.20112,"eighty":-0.835938,"marketCap":79659893},{"date":"2024-09-06","current":-0.841617,"twenty":-16.505977,"median":-5.170108,"eighty":-0.835938,"marketCap":73021568},{"date":"2024-09-13","current":-1.137226,"twenty":-16.505977,"median":-5.147777,"eighty":-0.83478,"marketCap":98669640},{"date":"2024-09-20","current":-1.217214,"twenty":-16.505977,"median":-5.134847,"eighty":-0.83478,"marketCap":105609707},{"date":"2024-09-27","current":-1.140703,"twenty":-16.505977,"median":-5.095109,"eighty":-0.83478,"marketCap":98971382},{"date":"2024-10-04","current":-1.140703,"twenty":-16.505977,"median":-5.072443,"eighty":-0.83478,"marketCap":98971382},{"date":"2024-10-11","current":-1.158092,"twenty":-16.505977,"median":-5.048338,"eighty":-0.83478,"marketCap":100480092},{"date":"2024-10-18","current":-1.213736,"twenty":-16.505977,"median":-4.989452,"eighty":-0.83478,"marketCap":105307964},{"date":"2024-10-25","current":-1.262425,"twenty":-16.38143,"median":-4.952905,"eighty":-0.83478,"marketCap":109532353},{"date":"2024-10-31","current":-1.217214,"twenty":-16.38143,"median":-4.91148,"eighty":-0.83478,"marketCap":105609707},{"date":"2024-11-08","current":-1.133748,"twenty":-16.134656,"median":-4.833629,"eighty":-0.83472,"marketCap":98367898},{"date":"2024-11-15","current":-1.102479,"twenty":-16.134656,"median":-4.815435,"eighty":-0.83472,"marketCap":95350478},{"date":"2024-11-22","current":-0.959435,"twenty":-14.698849,"median":-4.78439,"eighty":-0.83472,"marketCap":82979055},{"date":"2024-11-29","current":-1.053635,"twenty":-13.999154,"median":-4.777025,"eighty":-0.83472,"marketCap":91126090},{"date":"2024-12-06","current":-0.156999,"twenty":-13.760912,"median":-4.73255,"eighty":-0.829018,"marketCap":13578390},{"date":"2024-12-13","current":-0.129088,"twenty":-13.700037,"median":-4.688598,"eighty":-0.823724,"marketCap":11164454},{"date":"2024-12-20","current":-0.123052,"twenty":-13.429478,"median":-4.649664,"eighty":-0.812813,"marketCap":10642441},{"date":"2024-12-27","current":-0.126366,"twenty":-13.355074,"median":-4.638411,"eighty":-0.80799,"marketCap":10929095},{"date":"2025-01-03","current":-0.157033,"twenty":-13.283677,"median":-4.591531,"eighty":-0.800329,"marketCap":13581408},{"date":"2025-01-10","current":-0.157696,"twenty":-13.227311,"median":-4.56186,"eighty":-0.796224,"marketCap":13638739},{"date":"2025-01-17","current":-0.132611,"twenty":-13.155913,"median":-4.528367,"eighty":-0.79584,"marketCap":11469214},{"date":"2025-01-24","current":-0.132577,"twenty":-13.152155,"median":-4.502605,"eighty":-0.789888,"marketCap":11466196},{"date":"2025-01-31","current":-0.123506,"twenty":-13.11082,"median":-4.426601,"eighty":-0.782351,"marketCap":10681667},{"date":"2025-02-07","current":-0.119319,"twenty":-13.095789,"median":-4.275044,"eighty":-0.770729,"marketCap":10319577},{"date":"2025-02-14","current":-0.114644,"twenty":-12.919174,"median":-4.16741,"eighty":-0.746719,"marketCap":9915242},{"date":"2025-02-21","current":-0.10955,"twenty":-12.716255,"median":-4.125642,"eighty":-0.737385,"marketCap":9474699},{"date":"2025-02-28","current":-0.096258,"twenty":-12.659889,"median":-4.0795,"eighty":-0.732718,"marketCap":8325062},{"date":"2025-03-07","current":-0.095211,"twenty":-12.492293,"median":-4.029264,"eighty":-0.725698,"marketCap":8234539},{"date":"2025-03-14","current":-0.094827,"twenty":-12.348747,"median":-3.987402,"eighty":-0.722917,"marketCap":8201348},{"date":"2025-03-21","current":-0.105538,"twenty":-12.242026,"median":-3.90577,"eighty":-0.711716,"marketCap":9127696},{"date":"2025-03-28","current":-0.103968,"twenty":-11.838443,"median":-3.861814,"eighty":-0.704819,"marketCap":8991912},{"date":"2025-04-04","current":-0.114499,"twenty":-10.872596,"median":-3.767624,"eighty":-0.697715,"marketCap":9157568},{"date":"2025-04-11","current":-0.118691,"twenty":-10.624723,"median":-3.541277,"eighty":-0.695792,"marketCap":9492803},{"date":"2025-04-17","current":-0.121181,"twenty":-10.441636,"median":-3.386242,"eighty":-0.690627,"marketCap":9691953},{"date":"2025-04-25","current":-0.305981,"twenty":-10.150385,"median":-2.970388,"eighty":-0.680801,"marketCap":24472182},{"date":"2025-04-30","current":-0.117902,"twenty":-10.063067,"median":-2.859389,"eighty":-0.677139,"marketCap":9429739}],"updateTime":1746103012110}}}